Q3 Beats, Then ZYN Spends It: A 25% Per-Pouch Reset Takes Q4 U.S. Profit to Zero, and at ~24x PM Stays a Hold

Results vs. Consensus

The bar for this print moved twice. In July, management guided Q3 adjusted EPS to $2.20–$2.25, including an 8-cent currency drag. On September 8 it lifted that range to $2.29–$2.34 for currency only, as the drag became a 1-cent benefit, and the Street settled near $2.30. PMI cleared both the consensus and the top of its own updated range. The quality of the beat is mixed in an instructive way: the international business and pricing over-delivered, while the U.S. segment and the tax line held the headline back.

Q3 2026 Scorecard

Year-over-Year Comparison (Q3 2026 vs. Q3 2025)

Sequential Comparison (Q3 2026 vs. Q2 2026)

First Nine Months of 2026

Quality of Beat

Revenue: Organic growth of +7.1% was close to Q2's +7.6% and far above Q1's +2.7%, but the mix flipped from the first half. International Combustibles grew +7.8% organically on +8.9% pricing and flat volume, helped by the one-off distribution-terms benefit. International Smoke-Free grew only +3.4% organically, on +2.7% volume and almost no price ($21M), as HTU shipments of 41.5 billion units lapped a strong prior-year quarter and Japan inventory drained. The U.S. added +22.7%, nearly all of it price ($153M), as last September's free-can promotion fell out of the base. Currency cost $155M (about 1.4 points) and divestitures $27M, which together separate the +5.5% reported growth from the +7.1% organic rate.

Margins: Adjusted gross margin rose 0.8pp to 68.7% on pricing, smoke-free scale and manufacturing productivity, partly offset by energy-related input costs that are now reaching the P&L. Adjusted operating margin rose 1.6pp to 44.7%, its best level of the coverage period. Two items flatter that figure: adjusted marketing, administration and research costs grew about 3.5%, below revenue growth, helped by G&A productivity and a prior-year comparison that included combustible-related items, and corporate expenses swung to a $5M credit on currency. PMI also reported more than $2B of cumulative gross cost savings since 2024, which meets its 2024–2026 target ahead of schedule. The margin is real, but Q4 gives part of it back.

EPS: The bridge from $2.24 to $2.36 consists of +$0.19 from operations, -$0.08 from a higher tax rate (21.5% against 18.7% in a prior-year quarter with discrete benefits), +$0.02 from interest and -$0.01 from currency. Excluding the tax comparison, adjusted EPS would have grown about 9%. Reported EPS fell 4.9% to $2.12, mainly because of a $0.06 fair value loss on listed equity stakes in India and Sri Lanka (against a $0.07 gain a year ago) and a $0.04 Dutch pension buy-out loss, while the prior-year quarter included $0.14 of favorable tax items. None of these affects the operating trend.

Segment Performance

Segment Scorecard: Q3 2026

Segment revenues sum to $11,437M against the $11,438M total because of rounding in the issuer's tables. Operating companies income (OCI) is reported by business unit: International adjusted OCI was $4,940M (+8.8% reported, +10.8% organic), and U.S. adjusted OCI was $171M (+1.9% reported, +1.5% organic). U.S. OCI on a reported basis was a loss of ($34M) after $201M of acquisition amortization and $4M of restructuring. Total adjusted OCI was $5,112M (+10.5% organic).

Net Revenue by Product Category

International Smoke-Free: Demand Accelerated, Revenue Did Not

This is the quarter in which the segment's two measures diverged most. Revenue grew +0.7% reported and +3.4% organically, the slowest rate of the year, and gross profit grew +3.3% organically at a flat 70.0% margin. Demand moved the other way: total adjusted in-market sales accelerated to +8.0%, IQOS HTU adjusted IMS to +7.1% from +5.1%, VEEV shipments grew +61.6%, and modern oral pouches grew +20.6% to 0.5 billion units. The gap is shipment timing. PMI shipped HTUs ahead of demand in late 2025 and in the first half to prepare for Japan's two excise steps, and those inventories are now running down. Year to date the segment grew +9.9% organically with gross margin up 1.2pp to 70.0%, which is the better gauge of its run-rate.

"International smoke-free delivered excellent year-to-date results, with organic growth of almost 10% in net revenues and +12% in gross profit, driving +120 basis points of gross margin expansion to 70%. ... As expected, Q3 growth was slower due to shipment timing comparisons and related category mix." — Massimo Andolina, Group CFO

The price line is worth watching. Smoke-free price contributed only $21M, about half a point, and one analyst on the call estimated that price/mix slowed from about 3.5% in the first half to about 70 basis points. Management attributed it to the shipment comparison, category mix (fast-growing VEEV and oral carry lower revenue per unit than HTUs) and the timing of some IQOS price moves.

Assessment: The demand data are the most encouraging of the year, and they support the core of the bull case. Revenue will catch up as the inventory effect fades, and management guides Q4 international smoke-free to re-accelerate. We do not treat the soft quarter as a warning. We do note that a third quarter in a row of excise-related distortion makes the reported line hard to read until 2027.

International Combustibles: A Second Exceptional Quarter

Combustibles delivered another quarter management called better than it expected. Pricing rose +8.9% (+9.1% year to date), cigarette volume was flat at 158.0 billion against an industry decline of about 1.1%, category share rose 0.4pp to 25.9%, and Marlboro reached a record 11.4% share (+0.5pp). Net revenue grew +7.8% organically and gross profit +9.8%, with gross margin up 1.3pp to 68.5%. Volume strength again came from Turkey, Indonesia and Egypt, markets where smoke-free products are banned or barely present, which creates an unfavorable geographic mix. The quarter also benefited from restructured distribution terms in certain markets, which management does not expect to recur at the same level.

"Our combustible business delivered a standout Q3 performance, exceeding our expectations through a combination of stable volumes, high single-digit pricing, and a specific benefit from the restructuring of distribution terms in certain markets." — Massimo Andolina, Group CFO

Assessment: The cash engine did more than fund the transition this quarter. It carried the group. Full-year pricing is now guided above 8% and cigarette volume to a decline similar to the year-to-date -1.2% (from -2% to -3%), both raised again. But the distribution-terms item is a one-off, and a Q3 that depended this heavily on combustibles is the lower-quality half of the beat. We bank the cash and keep modeling a fade.

U.S.: Revenue Up 23%, Profit Up 2%

The U.S. segment's headline growth reflects its comparison base. Net revenue rose +22.7% to $845M, mostly from price ($153M of variance) as the September 2025 free-can promotion dropped out of the base. ZYN shipments grew +4.2% to 3.2 billion pouches, +13% excluding that promotion and +10% sequentially. Adjusted gross margin rose 0.7pp to 64.4% despite start-up costs at the new Colorado plant. But adjusted OCI grew only +1.5% organically to $171M, down from $279M in Q2, as segment SG&A rose to about $370M to support the new ZYN range. Year to date, U.S. adjusted OCI is $550M, down 41.1% organically.

"Following several quarters of volume progress below the category growth rate, ZYN's category offtake share increased by an estimated 1.4 points from June to September, demonstrating the incremental contribution of the new variants and interest from competitor pouch consumers." — Massimo Andolina, Group CFO

Assessment: The share gain is the first hard evidence that the expanded range works, and it answers the portfolio-gap question that drove our April and July caution. The problem is the price of that answer: a quarter of +22.7% revenue growth produced almost no profit growth, and Q4 profit goes to about zero. The U.S. has become a volume-recovery story with a lower price per pouch, and a lower margin than the one priced in during 2024–2025.

IQOS by Geography

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Confident on the international business and candid, almost blunt, about the cost of the U.S. plan. In his first call as Group CFO, Massimo Andolina gave more quarter-level guidance than PMI usually provides: a dollar run-rate for U.S. spend, a near-zero Q4 U.S. profit and the 25% per-pouch arithmetic, all stated before analysts asked. The posture shifted from July's all-out enthusiasm about ZYN to a more defensive argument that the investment is temporary and the rest of the group can absorb it, and the call was least convincing on what U.S. profit looks like in 2027.

1. Grading the July Commitments

In July we downgraded to Hold and set seven items to check this quarter. The international items mostly delivered. The U.S. items delivered on volume and missed on profit.

"We are pleased with the initial consumer reaction and sequential increase in category share, even as we have yet to reach full commercial deployment of the first wave of expansion." — Massimo Andolina, Group CFO

Assessment: The scorecard explains why we hold the rating. The parts of the thesis we were paying for in July, IQOS and the international franchise, came through. The part we flagged as unproven, the U.S. recovery, came through on volume but at a cost that the July framework did not include. The overall result is neutral, not a reason to change the rating.

2. The Beat Is Spent: "Midpoint or Lower Half"

The key change on the call was in the guidance language, not the ranges. The ex-currency EPS range (+7.5% to +9.5%) and the organic operating income range (+7% to +9%) were reaffirmed, and organic revenue now leans to the middle or upper half of +5% to +7%. But management steered both profit measures to the midpoint or lower half. The dollar EPS range fell to $8.29–$8.44 from the September 8 figure of $8.35–$8.50 as the currency benefit shrank to $0.18 from $0.24, partly on euro weakness. With nine-month adjusted EPS at $6.52, the new range implies Q4 EPS of $1.77–$1.92, and the lower half implies $1.77–$1.85. That compares with roughly $1.85–$2.05 implied by the September guide after the Q3 range, so the Q3 beat of a few cents was more than given back in Q4.

"However, considering the significant H2 step-up in U.S. investments and the cost impact of ongoing geopolitical tensions, we see the full year delivery more likely to be at the midpoint or lower half of both brackets." — Massimo Andolina, Group CFO

Management's own breakdown puts about one point of the shortfall on geopolitics (half a point of energy-driven inflation, half a point of Ukraine supply-chain damage) and states that the business would otherwise land in the mid-to-upper half. That framing implies the U.S. step-up is absorbed inside the range, which is true for 2026 but leaves the 2027 effect open.

Assessment: This is a modest cut presented as a reaffirmation. Q4 EPS of about $1.81 at the middle of the lower half would grow about 6% against Q4 2025's $1.70, close to Q3's tax-depressed +5.4% and far below the first half's mid-teens growth. For a stock priced at ~24x, the direction matters more than the cents: July's trim was currency only, and this is the first operating steer lower this year.

3. ZYN's 25% Per-Pouch Price Reset

The structural news is a pricing decision. PMI started selling ZYN Ultra in 20-pouch cans over the summer, and from October it moves the 1.5mg, 3mg and 6mg flagship variants, "a large majority of our volumes," from 15 to 20 pouches at the same shelf price. Management also funds retail support to clear the remaining 15-pouch stock. The stated aim is to "align the value proposition across the portfolio and optimize ZYN's price premium," in plain terms to narrow the gap to discounted competitors that has cost ZYN share since 2025.

"The transition to 20 pouch cans represents a significant investment in consumer value, which all else equal, translates into approximately 25% less revenue per pouch." — Massimo Andolina, Group CFO

Asked whether the bigger can would cut or lift consumption, management said only "let's wait and see," then offered the argument that users in mature pouch markets consume high single-digit pouches per day against low single digits in the U.S. today. Management also said the revenue effect lags for three quarters, which places it in Q1–Q3 2027.

Assessment: This is the most important change to the U.S. thesis since the 2024 supply shortage. ZYN gives up part of its premium to defend share, which is a sound long-term decision for a category leader facing aggressive discounting, but it resets the unit economics we and the Street had built in. A 25% cut needs about 33% more pouches to keep revenue flat. We do not expect volume to close that gap in 2027, so U.S. revenue growth depends on elasticity that management has chosen not to quantify.

4. The U.S. P&L: A "Unique" Q4 and a 2027 Run-Rate

Management laid out the U.S. cost path in unusual detail. Segment SG&A rose to about $370M in Q3, rises about 10% more in Q4 to support the "When It Clicks" campaign and the can transition, and the Q3 level is the run-rate for 2027. Combined with the per-pouch reset, sell-out support and under-absorbed Colorado capacity, Q4 U.S. adjusted OCI goes to "around 0 or slightly negative." That puts full-year U.S. adjusted OCI near $550M, against $958M in the first nine months of 2025 alone.

"Indeed, taking the aggregate impact of these actions and the expansion of our manufacturing capacity to support future growth, Q4 will be a unique quarter of investment. We expect an abnormally low level of U.S. profitability in the fourth quarter with adjusted OCI around 0 or slightly negative." — Massimo Andolina, Group CFO

Management argues that 2027 improves on Q4 because spend stops rising while volume grows and Colorado utilization improves. It did not say whether 2027 U.S. profit grows from the depressed 2026 base, and it noted that "the Q3 level of spend" is "sufficient to support the brand," meaning that a roughly $1.5B annual spend level is now permanent.

Assessment: The "unique quarter" label is accurate for the size of the Q4 charge, but most of the cost is not one-off. A permanent ~$1.5B annual spend level and a 25% lower price per pouch mean U.S. profit restarts in 2027 from a lower base. That turns the U.S. leg from a growth driver into a recovery we must underwrite, at a time when the stock prices growth.

5. ZYN Share Gains Versus the Scanner Data

The release puts ZYN's U.S. category share gain at more than 100 basis points from June to September on a third-party estimate, and the CFO said 1.4 points. Shipments grew +4.2% to 3.2 billion pouches, +13% excluding last September's free-can promotion and +10% sequentially. One questioner noted that third-party scanner data pointed to a mid-single-digit volume decline in Q3. Management repeated the promotion-adjusted figure and pointed to distribution of new variants, which by definition fills the trade pipeline ahead of consumer offtake.

"Sequentially, shipments increased by 10% versus Q2, reflecting category expansion and the ongoing launch of new portfolio variants, which have contributed to an improvement in our category share and should position us well for future growth." — Massimo Andolina, Group CFO

The regulatory base is strong: the FDA authorized 11 ZYN Ultra variants on August 21, bringing ZYN to 31 PMTA-authorized variants, more than any other nicotine brand, alongside the June MRTP for 20 flagship variants. Management guides Q4 shipments broadly in line with to modestly above Q3.

Assessment: The share data and the shipment data are consistent with a portfolio that is winning back users, but part of the +4.2% is pipeline fill for new variants. The cleanest evidence will come in Q1 2027, after the can transition, when shipments and offtake should converge. Until then we treat the U.S. as stabilizing, not re-accelerating.

6. IQOS Re-Accelerates, and the Growth Base Is Broader

IQOS HTU adjusted in-market sales grew +7.1% in Q3 (from +5.1% in Q2) and +7.7% year to date despite Japan's excise steps and Poland's flavor ban. Excluding those two markets, growth was about +10% in the quarter and +10.8% year to date, above 2025's +10.6%. More large markets now grow at double digits: Italy, Greece, Spain, the Netherlands, the U.K. and Germany. IQOS reached 9.9% of cigarette and heated-tobacco volume where present (+1.0pp), and PMI's combined international share of cigarettes and HTUs passed 30% for the first time.

"Excluding these 2 markets, adjusted IMS growth remained around +10% in the quarter and almost +11% year-to-date, consistent with the strong underlying trajectory of the business and the durability of demand across our geographic footprint." — Massimo Andolina, Group CFO

Management also highlighted the mainstream DELIA and SENTIA ranges, which together now exceed the size of the closest heated-tobacco competitor, and BONDS by IQOS, an alternative heating technology aimed at entrenched smokers that is in initial launch areas, including some prefectures in Japan.

Assessment: This is a clear rebound from Q2's trough and strong support for Bull #2. The breadth matters more than the rate: a franchise growing at double digits across a dozen large markets depends less on Japan than it did two years ago.

7. Japan: Pantry Loading Again, and a Calmer 2027 Calendar

Japan HTU adjusted IMS returned to growth at +3.4%, but +1.3% excluding consumer pantry loading ahead of the October 1 JPY20 increase, the second step after April's JPY40. IQOS held about 68% of the heated-tobacco category despite raising prices more than competitors in April. Management expects a softer Q4 as the loading reverses and still expects Japan to grow for the full year. From April 2027 the excise schedule raises both cigarettes and heated tobacco moderately each year, about JPY12, which removes this year's one-sided pressure on HTUs.

"While the April 2027 increase will mark the third change in 12 months, with a potential cumulative impact on the consumer, we remain excited about the category's midterm growth potential in Japan." — Massimo Andolina, Group CFO

Assessment: Japan is behaving as guided, with share intact through more than 10% of price in one year. The new caution is the "third change in 12 months" remark, which signals that the April 2027 step could still slow consumers who have already absorbed two increases. Japan remains a modest 2027 risk, not a 2026 one.

8. Shipment Phasing: Why Smoke-Free Revenue Lagged Demand

HTU shipments grew only +1.5% to 41.5 billion, at the high end of PMI's previous expectations, while IMS grew +7.1%. Management now expects full-year HTU shipments to grow slightly below IMS, with Q4 shipments of 39.5–40.5 billion units, because the October Japan step drew less pantry loading than April's and trade inventories built for the excise year are being run down.

"We now expect HTU shipment growth to be slightly below adjusted IMS growth for the full year, with the Q3 dynamic of adjusted IMS growing faster than shipments to continue in Q4, notably due to the in-year phasing impact of price changes in Japan." — Massimo Andolina, Group CFO

Assessment: Lower inventory is healthier than higher inventory, and it releases working capital, which supports the record cash-flow guide. But it also means that Q4 international smoke-free revenue re-accelerates against an easier comparison rather than on fresh demand. Investors should read Q4 revenue growth with that in mind.

9. Combustible Pricing Above 8%, With a One-Off Inside

Cigarette pricing of +8.9% delivered $565M of the group's $739M price variance. Volume was flat while the industry fell 1.1%, and Marlboro set another share record at 11.4%. Management raised full-year pricing to above 8% and expects cigarette volume to fall only about as much as the year-to-date -1.2%. The quarter also included a favorable restructuring of distribution terms in certain markets, which management did not quantify and does not expect to be significant in Q4.

"We now expect full-year pricing of above 8% with the net revenue impact partially offset by a more unfavorable geographic mix." — Massimo Andolina, Group CFO

Assessment: Combustible pricing near 9% is unusually high for PMI, and it is the reason the group can fund the U.S. without missing its range. The risk is that 2027 pricing normalizes as the U.S. spend stays, which would compress the group's earnings growth just as the U.S. price cut reaches revenue.

10. Geopolitics Costs About One Point of Growth

The Middle East conflict, a minor cost in Q2, became a measurable one. Energy-related inflation raised input and shipping costs in Q3, with a larger effect in Q4 as new contract prices take effect. Separately, three strikes on PMI supply-chain facilities in Ukraine destroyed goods. Management sizes each at about half a point of 2026 EPS growth.

"Overall, we estimate the impact on full-year adjusted diluted EPS growth to be around half percentage point, in addition to a similar-sized headwind from disruptions in Ukraine. This results in a combined impact of approximately one point of growth for the year." — Massimo Andolina, Group CFO

Assessment: One point is small for a consumer company with energy-intensive inputs, and management is right that peers have flagged more. But the effect is rising into Q4, the contracts that delayed it will reprice, and the exposure carries into 2027 if energy prices stay high. We treat it as a real, if modest, 2027 headwind.

11. VEEV and International ZYN Keep Scaling

VEEV shipments grew +61.6% in Q3 and +68% year to date to 4.0 billion equivalent units, extending its lead as Europe's top closed-pod brand, with promising results outside Europe in Indonesia, Egypt and Malaysia, and in South Korea after its August launch. International modern oral grew +20.6% to 0.5 billion pouches, ZYN is now in 62 international markets, and like-for-like international ZYN shipments grew +6.3% year to date with a step-up in Q3. Ex-Nordics ZYN IMS grew +30% year to date. Total international oral volume turned positive (+0.5%) as pouch growth offset legacy Nordic snus.

"E-Vapor shipments grew by a remarkable +62%, demonstrating the increasing scale and importance of our multi-category portfolio and VEEV's role within it." — Massimo Andolina, Group CFO

Assessment: These are small businesses growing fast, and they make PMI's smoke-free growth less dependent on a single device. They will not offset U.S. pressure in 2027, but they widen the base under Bull #1.

12. Germany's Excise Increase and Other Regulatory Moves

Germany passed a law that raises tobacco excise sharply over four years from January 2027. Management stressed that the law retains heated tobacco's tax advantage over cigarettes and that PMI's brand portfolio, led by Marlboro and Marlboro Crafted, can compete at every price point. It also cited regulatory changes in Argentina as a step toward entering that heated-tobacco market next year, following Taiwan's opening in 2025.

"First and foremost, the differential with HTU has been retained, and therefore, HTU retains a tax advantage versus the underlying cigarette tax." — Massimo Andolina, Group CFO

Assessment: Germany is a net neutral for PMI: cigarette volumes are at risk to illicit trade, but the retained HTU differential should speed switching in a market where IQOS already grows at double digits. Argentina is upside not in our numbers. The regulatory balance this quarter is mixed, as in July.

13. Record Cash Flow, Lower Leverage, a Bigger Dividend

Operating cash flow was $5,352M in Q3 (+19.9%) and $10,445M for nine months (+38.8%), and management reaffirmed a record ~$13.5B for the year. Net debt fell to $40,879M from $43,963M at year-end, taking net debt to adjusted EBITDA to 2.17x from 2.53x, close to the ~2.0x year-end target. In September PMI raised its quarterly dividend 8.8% to $1.60, or $6.40 annualized, its 19th consecutive annual increase. Share repurchases remain off. PMI plans an Investor Day in Q2 2027.

"We also expect to generate a record level of approximately $13.5 billion in operating cash flow, testament to our strong cash flow generation." — Massimo Andolina, Group CFO

Assessment: Cash flow is the strongest support for the shares, and with leverage near target the question of buybacks will return in 2027. The Investor Day is the natural place to reset the U.S. framework and the long-term algorithm. We expect it to be the next real catalyst.

Guidance & Outlook

The guidance tells two stories. Above the profit line, the revenue and volume frames all moved up: total volume now grows for a sixth year, cigarette volume declines less, pricing exceeds 8%, and organic revenue leans to the upper half. At the profit line the frames moved down: organic operating income and EPS lean to the lower half. The difference between the two is the U.S. investment and the geopolitical cost, so the group sells more and keeps less of it in Q4.

Implied Q4: Adjusted EPS of $1.77–$1.92 on the full range and about $1.77–$1.85 on the lower half, against $1.70 in Q4 2025, which is growth of about 4% to 9% on the lower half. Ex-currency, with a currency headwind of about $0.02 in Q4 (the full-year benefit of $0.18 is below the nine-month $0.20), the range is $1.79–$1.94. Q4 includes the full effect of the can transition, the 10% U.S. spend increase and the strongest geopolitical cost of the year, offset by an international smoke-free re-acceleration.

Street at: Full-year consensus sat near $8.41, above the new $8.365 midpoint and well above the lower half, so 2026 estimates should edge down by a few cents. The bigger revision risk is 2027, where the 25% per-pouch reset and the permanent U.S. spend level arrive together. Some of that was already in estimates after the can change was previewed in September.

Guidance style: Conservative in form and specific in content, a change from the prior CFO. Andolina gave quarter-level numbers that make Q4 hard to miss, which suggests the team prefers to reset expectations early rather than defend a range. That is good for credibility and poor for near-term upside surprises.

Analyst Q&A Highlights

Why the Profit Steer Fell After a Beat

The first question went straight to the central tension: Q3 beat the company's own guide on revenue and EPS, yet management pointed the full year to the lower half. The questioner asked whether the U.S. plan was now costing more than budgeted. Management put the steer on geopolitics and argued that the U.S. step-up was being absorbed.

Q: "Your Q3 came in better on both the top line and EPS versus your guidance for the quarter. Yet, as you mentioned, you are pointing to the middle or lower half of your full-year organic OI growth guidance, and it sounds like on your EPS growth guidance as well. I know you called out the higher cost pressures from the ongoing geopolitical tensions, but I really did want to verify if you are also now planning on spending more in the U.S."
— Bonnie Herzog, Goldman Sachs

A: "We guided you through a full year impact of half a point of EPS. ... We guided you to another half a point that is coming from disruptions, which are kind of one-off things that have happened in Ukraine ... Quite frankly, if you look at that and you look at our guidance, that constitutes one point, and it means that just that one, if we had not had those impacts, we would be mid to higher half of the range."
— Massimo Andolina, Group CFO

Assessment: The answer was clear about 2026 and incomplete about 2027. Management did confirm in a follow-up that Q3's U.S. spend is "a good proxy for the run rate" next year, which is the more important disclosure: the investment is not a two-quarter event. The geopolitical explanation for the steer is credible, but it also means the U.S. step-up has already used the room that a strong international business created.

How the New ZYN Variants and the 20-Pouch Can Change Consumer Behavior

A follow-up asked how the new ZYN variants performed against internal plans, how incremental they are to the flagship, and whether bigger cans would raise or lower consumption. Management was enthusiastic about the variants and anecdotal on the can.

Q: "And then second, on the move to 20 pouches in each of the ZYN can, I am curious how you see this impacting consumer behavior, if at all. For instance, do you see it, I do not know, as a headwind to volumes, or could it be a possible tailwind if consumers now consume more since they have more pouches in each can they buy?"
— Bonnie Herzog, Goldman Sachs

A: "We have seen an inflow, both of legal-age smokers that are coming to the category, but also of competitors' users and people, in the case of 9 mg and 11 mg, that had left ZYN to go to competitors' propositions in higher nicotine levels and who have come back into ZYN, thanks to those launches. ... Regarding your question on consumer behavior. Well, Bonnie, let's wait and see. I can tell you my personal experience. When I have more in the pocket, I tend to consume more."
— Massimo Andolina, Group CFO

Assessment: The variant data are encouraging and consistent with the share gain, especially the return of lapsed users who had left for stronger competitor pouches. On the can, management offered no elasticity estimate and no volume target. A 25% price cut on most of the volume is too large a decision to rest on anecdote, and the lack of a stated break-even is the main gap in the U.S. story.

Whether U.S. Profit Falls in 2027

A question asked directly whether U.S. operating profit would decline in 2027, given +1.5% growth on an easy Q3 comparison, a Q4 near zero and continued investment. Management declined to guide but offered the pieces: volume growth, a flat cost base at the Q3 level, better Colorado absorption, and a three-quarter revenue lag from the price reset.

Q: "The EBIT this quarter in the U.S. is growing only 1.5% on a very easy comp. For Q4, you are saying it would be 0 or slightly negative. Given that the investments will continue into next year, is it fair to assume that the U.S. EBIT would decline next year?"
— Pallav Mittal, Barclays

A: "Therefore, you can assume that with volume growth continuing from the category and from our ability to retain or even increase share, the absorption of those costs is going to be better, including the investments that we have made in Colorado for the manufacturing facility. ... One thing to keep in mind is the fact that obviously the 25% price optimization that we are making in Q4 will have a lagging effect for 3 quarters on the revenue level, but on a growing volume."
— Massimo Andolina, Group CFO

Assessment: The answer did not deny the premise. Against full-year 2026 U.S. adjusted OCI of about $550M, three quarters of lower revenue per pouch and a cost base held at the Q3 level point to flat-to-lower U.S. profit in 2027 unless volume grows faster than the category. We model it roughly flat, which is below where the thesis stood in July.

Shipments Ahead of Scanner Data

A question noted that +4.2% U.S. ZYN shipments compared with a mid-single-digit decline in third-party scanner volumes, and asked whether restocking explained the gap. Management pointed to the promotional comparison and to distribution of new variants.

Q: "The reported shipment number, the just over +4% in the U.S. on volumes, does seem to be ahead of the scanner data that we've seen, which would have suggested around mid-single digit volume decline in Q3. I was just wondering if that delta is explained by a degree of restocking or if there are other factors in play that would explain this difference."
— Andrei Andon, Jefferies

A: "We are actually removing that unfavorable comparison, growing 13% in the quarter net of that comparison. ... So over the course of the quarter, there was obviously increase of distribution. We believe that for those variants, we are now fully covered in terms of distribution."
— Massimo Andolina, Group CFO

Assessment: The promotion adjustment explains the year-on-year comparison, not the gap to the scanner data, and the answer effectively confirmed that pipeline fill for new variants lifted Q3 shipments. Scanner panels also miss some channels, so the gap may be smaller than it looks. Still, this is why we treat the +1.4-point share gain as the better signal and the shipment growth as partly one-off.

Inflation in Q4 and the Offsets for 2027

A question asked whether the inflation hit is larger than a point of profit in Q4 alone, and which levers can offset it now that the cost-savings target is met and pricing is already high. Management declined a quarterly split and pointed to supply-chain hedges and pricing power.

Q: "If you just isolate the fourth quarter, should we think of that as over a one-point drag on profit, and how do you view levers to offset the impact going forward?"
— Matt Smith, Stifel

A: "I'm not going to guide you, Matt, on the precise split of those elements across the various quarters. The Q4 is probably the quarter in which we are feeling it the most, purely from a timely perspective, because those higher priced inputs are coming in now. ... we have demonstrated this year and also in previous years that we have very strong pricing power, and we are entering 2027 with probably a super strong P&L at this point"
— Massimo Andolina, Group CFO

Assessment: By implication the Q4 cost is well above a point of profit growth, since most of the full-year half point lands in the second half, and in Q4 most of all. Management also conceded that its contract protections "cannot last forever." Pricing power is real, but the answer confirms that 2027 starts with an input-cost headwind on top of the U.S. investment.

HTU Shipments Trailing In-Market Sales

A follow-up asked about the new guidance that HTU shipments trail IMS for the year and whether trade inventory leaves 2026 at a normal level. Management tied the gap to the smaller October Japan step and described the inventory run-down as healthy.

Q: "You changed your guidance a bit for the heated tobacco IQOS shipment versus in-market sales growth guidance. I think now you expect shipments to slightly trail IMS. Can you talk about or give more detail on that gap, and how do you view inventory levels as you are exiting 2026?"
— Matt Smith, Stifel

A: "Given that our April pricing was of JPY 40, but our October pricing is of JPY 20, we are seeing obviously less pantry loading from the consumers given the smaller increase that is happening in the second half of the year as we saw in the first half of the year. Which means we entered into well-equipped from a shipment level and therefore with that phasing of shipments, IMS are going to run ahead slightly of shipments and therefore you will see inventories coming down, but always at a very healthy level, and therefore we also take the benefit on the working capital side."
— Massimo Andolina, Group CFO

Assessment: A clean, credible answer. Inventory falling while demand accelerates is the healthy combination, and it means 2027 HTU shipments start from a lower base that is easier to grow from. It also explains why Q3 smoke-free revenue understates demand.

International Smoke-Free Puts and Takes for 2027

A question asked for the main factors behind international smoke-free growth next year, given lapping Poland, a calmer Japan calendar and a German tax change. Management declined to guide but made the case that underlying IQOS growth is accelerating and broadening.

Q: "First, could you talk a little bit about puts and takes for international smoke-free growth next year? Realizing you are not going to give us guidance today. But clearly 2026 was an extraordinary year."
— Eric Serotta, Morgan Stanley

A: "You saw that we presented year-to-date 7.7% adjusted IMS growth. If you take out the impact from Japan and Poland, we are at 10.8% IMS growth. You could compare that with 2025, which was at 10.6%, which means that you see that the momentum is there and is actually increasing. ... Now that we move into next year and you have a JPY 12 increase across the board for HTUs and for cigarettes, you may argue that that is a more progressive increase and something by which there is going to be less of a shock wave for the category itself."
— Massimo Andolina, Group CFO

Assessment: The strongest answer on the call. The international case for 2027 is better than for 2026: Poland laps, Japan's tax burden is shared with cigarettes, Germany keeps the HTU tax gap, and more large markets grow at double digits. This is the main reason we do not go to Underperform despite the U.S. reset.

Why Smoke-Free Price and Mix Softened in Q3

The same questioner estimated that international smoke-free price/mix fell from about 3.5% in the first half to about 70 basis points in Q3 and asked why. Management listed the shipment comparison, category mix and the timing of some IQOS price moves.

Q: "It does seem like the price mix or the implied price mix in international smoke-free was a little bit softer this quarter. I think it ran about 3.5% in the first half, closer to, I get 70 basis points in the third quarter. Just wondering what's happening there."
— Eric Serotta, Morgan Stanley

A: "There is therefore category mix within that, when you want to take that to revenues. And one third element, there have been certain pricing decisions, timing of certain pricing decisions, especially in IQOS, that have been made and which have hit the quarter, and that's all, but nothing else on that is of any concern to us."
— Massimo Andolina, Group CFO

Assessment: A plausible but unquantified answer. Category mix is a structural drag as VEEV and pouches grow faster than HTUs at lower revenue per unit, and that drag will persist. Price timing should reverse. We assume smoke-free price/mix recovers to low single digits, not to the first half's level.

What They're NOT Saying

1. What U.S. profit looks like in 2027. Management gave the cost run-rate and the revenue lag but declined to say whether U.S. operating income grows next year, deferring to February. With Q4 near zero and a 25% lower price per pouch, that is the single most important number for 2027 estimates, and it is missing.
2. ZYN consumer offtake volume. PMI gave share (+1.4 points) and shipments (+4.2%), but not offtake growth, the metric it has used in past quarters. Asked about a scanner-data decline, management repeated the shipment figure. The absence suggests offtake volume was not yet growing in Q3.
3. The elasticity behind the 20-pouch decision. No break-even volume, no consumption-per-user target and no expected share outcome accompanied a cut of about 25% in revenue per pouch on most of the U.S. volume. "Let's wait and see" is not a framework.
4. The size of the distribution-terms benefit. The restructuring that helped combustible revenue is described as non-recurring, but its value was not disclosed, so investors cannot separate it from the underlying +7.8% organic growth.
5. IQOS ILUMA in the U.S. Neither the release nor the call mentioned ILUMA or a U.S. heated-tobacco timeline. In July it was a stated use of H2 investment. It remains unmodeled optionality.
6. Share repurchases. Leverage is 2.17x and falling toward the ~2.0x target on record cash flow, but the guide repeats "no share repurchases" with no word on when that changes. We expect the Investor Day to address it.
7. How competitors respond. A move to the 15-pouch price for 20 pouches invites a price response in a category already led by discounters, and management did not discuss it.

Market Reaction

• Pre-print setup (October 20 close): $199.90, up 24.6% year to date against +12.7% for the S&P 500, up 31.5% over twelve months and 6.6% over thirty days. The 52-week closing range was $144.33–$205.58, with the all-time closing high set on October 14, so PM entered the print about 2.8% below its record and at roughly 24x 2026 guidance.
• Premarket: Shares were indicated down about 2.5% in early premarket trading after the release, as the lower-half steer reached the headlines.
• Reaction session (October 21): The stock opened at $187.14 (-6.4%), traded as low as $184.00 (-8.0%), then recovered to close at $197.46, down 1.2% (-$2.44), on 5.8M shares, 1.2x the 30-day average. The S&P 500 rose 0.6%, so PM lagged by about 1.8 points. Altria fell 1.1% and British American Tobacco 0.4%.
• Following sessions: PM rose 2.2% to $201.74 on October 22 as the S&P 500 fell 1.2%, but Altria (+3.0%) and British American Tobacco (+2.7%) rose as much, which points to a sector rotation rather than a PM-specific re-rating. PM closed at $199.47 on October 23, 0.2% below the pre-print close.
• Since our July note: From the $194.30 Q2 reaction close to $199.47, PM gained 2.7% against +1.7% for the S&P 500 before dividends: a Hold that performed like one.

A gap-down that buyers reversed within the session. The open priced the lower-half steer and the zero-profit U.S. quarter as a profit warning. The 7.3% recovery from the low through the close says the market then decided otherwise: the ex-currency guide held, the Q3 beat was real, the international demand data were strong, and the U.S. cost was a temporary, stated investment, not a hidden problem. The CFO's quarter-level detail on the call probably helped, because it showed investors the size of the hit.

What the reversal does and does not say. A stock that recovers from -8% to -1% in one session has a deep holder base that treats weakness as an entry point, which caps near-term downside and is one reason we do not move to Underperform. But the recovery did not lift the stock above its pre-print level, and it left PM at ~24x a 2026 number that leans lower and a 2027 number the Street is still cutting. The market has forgiven the U.S. reset. It has not yet priced the possibility that the reset lasts longer than Q4.

Street Perspective

Debate: Is the ZYN Price Reset Smart Defense or a Value Trap?

Bull view: The bull camp argues that ZYN's premium had become too wide against aggressive discounters, that share loss was the larger long-term threat, and that a category leader with 31 authorized variants and the only pouch MRTP can afford to buy back share. On this view higher consumption per user and category growth rebuild revenue within a year, and the share gain since June shows the plan works.

Bear view: The bear camp sees a 25% price cut on most of the volume as an admission that ZYN's pricing power has eroded, and argues that price moves in a discount-led category tend to draw a competitive response. It points out that revenue needs about one-third more pouches just to stand still, and that the U.S. profit that once justified the Swedish Match premium is now close to zero for a quarter.

Our take: The decision is strategically defensible and financially expensive. We side with the bulls on the need to defend share and with the bears on the near-term economics. Until volume growth in 2027 proves the elasticity, the U.S. leg should be valued as a recovery, not as a growth engine.

Debate: Is Q4 a One-Off or the New U.S. Base?

Bull view: Supporters accept management's "unique quarter" framing. The can transition, the sell-out support and the campaign peak all land in Q4, spend stops rising after that, and volume growth on a fixed cost base restores profit through 2027.

Bear view: Skeptics note that the Q3 spend level is the stated 2027 run-rate, that the price cut weighs on revenue for three quarters of 2027, and that Colorado overheads stay high until volume fills the plant. On this view 2027 U.S. profit stays near the depressed 2026 level.

Our take: The bears have the better arithmetic for 2027. The size of Q4 is one-off, but the cost base and the price level are not. We model 2027 U.S. adjusted OCI roughly flat on 2026's ~$550M, a recovery from Q4's run-rate but not a return to 2025 levels.

Debate: Can the International Business Carry the Group in 2027?

Bull view: The bull case holds that international is 93% of revenue, IQOS IMS outside Japan and Poland is accelerating, Japan's 2027 tax calendar is calmer, Poland laps, VEEV and international ZYN add growth, and combustible pricing funds it all. On this view the group returns to its 8–10% operating income algorithm in 2027 despite the U.S.

Bear view: The bear camp notes that 2026 international profit rode combustible pricing near 9% and a one-off distribution benefit, both unlikely to repeat, while energy costs rise, Germany's excise increase pressures cigarette volume, and the April 2027 Japan step is the third in a year.

Our take: International carries the group, but probably at the low end of the algorithm once combustible pricing normalizes. That is enough to defend the dividend and the multiple, not enough to expand it.

Debate: After the Reversal, Is ~24x Still Fair?

Bull view: Optimists argue that a 3.2% yield, record cash flow, falling leverage and a re-accelerating IQOS franchise justify a premium consumer-staples multiple, and that the intraday reversal shows that investors see the U.S. cost as transitory.

Bear view: Skeptics argue that ~24x 2026 earnings is near the top of PMI's own historical range and well above its five-year average, for a year now guided to the lower half and a 2027 that faces U.S. and cost headwinds, so the stock leaves no room for a soft February guide.

Our take: Fair, not cheap. The multiple is full for the earnings path we now model, and the reversal removed the entry point the open briefly offered. We would buy nearer $170–175, about 19x forward earnings.

Model Update & Valuation Framework

Valuation: At the October 23 close of $199.47, PM trades at 23.9x our ~$8.33 FY26 estimate, against 23.3x at our July note on the same-year basis, and at 21.7x our ~$9.18 FY27 midpoint. The dividend yields 3.2%. Our fair value of $190–205 equals about 21–23x our ~$9.0 next-twelve-month EPS estimate. The lower 2027 estimate takes about $0.20 out of next year, and rolling the valuation forward a quarter adds back about the same, so the range is unchanged. Its $197.50 midpoint sits about 1% below the share price, and with the dividend the expected total return is about 2%, close enough to what we expect from the market to support a Hold.

Scenarios: The upside case, $215–230 (+8% to +15%), needs 24–25x on ~$9.1 next-twelve-month EPS: ZYN volume growth that outruns the price cut by mid-2027 and a February guide back at the 8–10% operating income algorithm. The downside case, $160–175 (-12% to -20%), applies 18–19.5x to ~$8.9 if the 2027 guide lands below the algorithm as U.S. profit stays depressed and combustible pricing normalizes, with the multiple drifting toward its longer-run average. The skew remains balanced-to-unfavorable, as in July, which is a Hold with a negative tilt.

Thesis Scorecard Post-Earnings

We grade the standing thesis carried since July. The international pillars strengthened, the combustible pillar over-delivered again, and the U.S. pillar improved on volume but weakened on economics. Valuation stays the dominant reason for the rating.

Overall: The thesis is unchanged in balance but changed in composition. The international pillars, which carry 93% of revenue, strengthened: IQOS re-accelerated, its growth spread across more markets, and combustibles delivered another record. The U.S. pillar moved from a portfolio problem to a price problem. ZYN now has the products and the regulatory clearances it lacked, but it is restoring share by giving up about a quarter of its revenue per pouch, and U.S. profit restarts from near zero. Valuation, which drove the July downgrade, is slightly richer than then, against a 2026 that leans lower and a 2027 that faces new headwinds.

Action: Maintain Hold; fair value $190–205 (about 21–23x next-twelve-month EPS of ~$9.0), conviction 6/10. In July we set two re-upgrade triggers: a reset toward 19–20x, or ZYN offtake re-acceleration that justified paying up. Neither happened: the multiple went up, and ZYN's recovery now relies on a price cut. We would move to Outperform on a pullback toward $170–175 (about 19x) with the international thesis intact, or if U.S. ZYN volume grows fast enough in H1 2027 to hold U.S. revenue flat through the per-pouch reset. We would move to Underperform if February's 2027 guide lands below 7.5% ex-currency EPS growth, if Q4 U.S. adjusted OCI is materially negative or U.S. profit is guided down for 2027, or if IQOS IMS outside Japan and Poland falls below high single digits. Into Q4 we watch U.S. revenue through the can transition, ZYN offtake against shipments, Q4 international smoke-free re-acceleration and HTU shipments of 39.5–40.5 billion, the size of the energy-cost hit, the February 2027 outlook and the Q2 2027 Investor Day.